Literature DB >> 10568558

Role of pacing in the treatment of vasovagal syncope.

R Sheldon1.   

Abstract

Patients with frequent vasovagal syncope have a markedly poor quality of life and are often resistant to treatment by standard pharmacologic approaches. Although the evidence is not conclusive, clinical vasovagal syncope is probably associated with some degree of bradycardia. Studies of temporary pacing during tilt-table testing have shown that pacing prevents syncope in more than half of patients who develop a vasovagal response. Three open-label studies of permanent pacing showed that pacing was associated with substantial improvement, and the prospective randomized Vasovagal Pacemaker Study reported an 85% relative risk reduction in patients randomized to pacemaker therapy compared with medical therapy. The roles of specific pacemaker modes in vasovagal syncope have not been determined, although early evidence indicates that rate-drop responsiveness is useful. The second Vasovagal Pacemaker Study may clarify the role of rate-drop responsiveness.

Entities:  

Mesh:

Year:  1999        PMID: 10568558     DOI: 10.1016/s0002-9149(99)00627-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  A Case of Cardiac Arrest for 31 Seconds During Recovery After Intravenous Sedation.

Authors:  Kaoruko Hamazaki; Yasuhiko Kato; Akari Hasegawa; Hiroko Yoneda; Nahoka Miyatani; Yoshihiro Momota
Journal:  Anesth Prog       Date:  2019

Review 2.  Strategy for the management of vasovagal syncope.

Authors:  Daniel M Bloomfield
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Predicting Vasovagal Responses: A Model-Based and Machine Learning Approach.

Authors:  Theodore Raphan; Sergei B Yakushin
Journal:  Front Neurol       Date:  2021-03-10       Impact factor: 4.003

4.  A Model of Blood Pressure, Heart Rate, and Vaso-Vagal Responses Produced by Vestibulo-Sympathetic Activation.

Authors:  Theodore Raphan; Bernard Cohen; Yongqing Xiang; Sergei B Yakushin
Journal:  Front Neurosci       Date:  2016-03-31       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.